Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study

Tuesday, May 14, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

-- PN-943 was safe and well tolerated with gut-restricted exposure --

Dose (mg)

PN-943 %RO

(max)

PTG-100 %RO*

(max)

PN-943 %RO

(AUC0-24)

PTG-100 %RO*

(AUC0-24)

100 mg (n=8)

62 ± 11.0

29 ± 7.7

933 ± 299

470 ± 195

300 mg (n=8)

83 ± 7.9

54 ± 10.0

1542 ± 158

746 ± 199

1000 mg (n=8)

94 ± 2.0

74 ± 9.7

1944 ± 84

1351 ± 186

1400 mg (n=8)

95 ± 3.6

N/A

2064 ± 164

N/A



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store